Novartis Gilenya® Approved in China

| By | China, Novartis

Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older.

Multiple sclerosis (MS) is categorized as rare disease in China with an estimated 30,000 MS patients in China. Gilenya is the 3rd most prescribed MS disease modifying treatment worldwide. Today, Gilenya is widely recognized by doctors with over 283,000 patients treated with Gilenya to date.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.